Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer

Value in Health

Volumn 16, Issue 5, 2013, Pages 789-796

  Rothrock, Nan E ^a   Jensen, Sally E ^a   Beaumont, Jennifer L ^a   Abernethy, Amy P ^b   Jacobsen, Paul B ^c   Syrjala, Karen ^d   Cella, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; patient reported outcomes; quality of life; symptoms

Indexed keywords

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; APPETITE; ARTICLE; BLOOD PRESSURE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CONVERGENT VALIDITY; DIARRHEA; FATIGUE; FEMALE; FEVER; FINANCE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HAIR LOSS; HUMAN; INTERNAL CONSISTENCY; KIDNEY CANCER; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL COMPREHENSIVE CANCER NETWORK FUNCTIONAL ASSESSMENT OF CANCER THERAPY KIDNEY SYMPTOM INDEX; NAUSEA; PAIN; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SLEEP DISORDER; SYMPTOM; VALIDATION STUDY; WEIGHT REDUCTION; WELLBEING;

CANCER; PATIENT-REPORTED OUTCOMES; QUALITY OF LIFE; SYMPTOMS;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84881668280     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.04.015     Document Type: Article

References (31)

1. American Cancer Society Cancer Facts & Figures 2012 2012 American Cancer Society Atlanta
2. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
3. A. Antonelli, A. Cozzoli, and D. Zani The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol BJU Int 99 2007 296 300
4. T.E. Hutson Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist 16 2011 14 22
5. M.E. Gore, and J.M.G. Larkin Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies Br J Cancer 104 2011 399 406
6. J.A. Sosman, I. Puzanov, and M.B. Atkins Opportunities and obstacles to combination targeted therapy in renal cell cancer Clin Cancer Res 13 2007 764s 769
7. D. Cella Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma Oncologist 16 2011 23 31
8. EuroQol Group Euro-Qol - a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
9. J.E. Ware Jr, and C.D. Sherbourne The MOS 36-item Short-Form Health Survey (SF-36), I: conceptual framework and item selection Med Care 30 1992 473 483
10. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
11. G. Harding, D. Cella, and D. Robinson Jr Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index Health Qual Life Outcomes 5 2007 34
12. D. Cella, S. Yount, and H. Du Development and validation of the Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI) J Support Oncol 4 2006 191 199
13. D. Cella, J.Z. Li, and J.C. Cappelleri Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial J Clin Oncol 26 2008 3763 3769
14. R. Bukowski, D. Cella, and K. Gondek Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer Am J Clin Oncol 30 2007 220 227
15. D. Cella, S. Yount, and P.S. Brucker Development and validation of a scale to measure disease-related symptoms of kidney cancer Value Health 10 2007 285 293
16. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
17. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009 U.S. Department of Health and Human Services, Food and Drug Administration Rockville, MD
18. D. Cella, D. Paul, and S. Yount What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN) Cancer Invest 21 2003 526 535
19. D.F. Cella, D.S. Tulsky, and G. Gray The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
20. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of The Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
21. D. Cella, S.K. Rosenbloom, and J.L. Beaumont Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer J Natl Compr Canc Netw 9 2011 268 278
22. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
23. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
24. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
25. D.L. Fairclough, and D.F. Cella Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions Qual Life Res 5 1996 321 329
26. C. Brunelli, M. Costantini, and P. Di Giulio Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree? J Pain Symptom Manage 15 1998 151 158
27. A.C. Justice, L. Rabeneck, and R.D. Hays Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms J Acquir Immune Defic Syndr 21 1999 126 133
28. C.L. Nekolaichuk, E. Bruera, and K. Spachynski A comparison of patient and proxy symptom assessments in advanced cancer patients Palliat Med 13 1999 311 323
29. R.J. Stephens, P. Hopwood, and D.J. Girling Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self- ratings? Qual Life Res 6 1997 225 236
30. A.S. Strömgren, M. Groenvold, and A. Sorensen Symptom recognition in advanced cancer: a comparison of nursing records against patient self-rating Acta Anaesthesiol Scand 45 2001 1080 1085
31. Z. Butt, J. Peipert, and K. Webster General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) Cancer 119 2013 429 437